4/19
09:18 pm
autl
How The Autolus Therapeutics (AUTL) Narrative Is Shifting With Recalibrated Targets And Fair Value [Yahoo! Finance]
Medium
Report
How The Autolus Therapeutics (AUTL) Narrative Is Shifting With Recalibrated Targets And Fair Value [Yahoo! Finance]
4/14
03:30 am
autl
Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development
Low
Report
Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development
4/9
08:15 am
autl
Autolus Therapeutics (AUTL) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $10.00 price target on the stock.
Low
Report
Autolus Therapeutics (AUTL) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $10.00 price target on the stock.
4/8
06:20 pm
autl
Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript [Seeking Alpha]
Neutral
Report
Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript [Seeking Alpha]
4/8
03:36 pm
autl
Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data [Yahoo! Finance]
Neutral
Report
Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data [Yahoo! Finance]
4/7
07:00 am
autl
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Autolus Therapeutics to Participate in Upcoming Investor Conferences
4/4
08:33 am
autl
Mizuho Lowers its Price Target on Autolus Therapeutics plc (AUTL) to $10 from $12 [Yahoo! Finance]
Low
Report
Mizuho Lowers its Price Target on Autolus Therapeutics plc (AUTL) to $10 from $12 [Yahoo! Finance]
3/31
09:46 am
autl
Autolus Therapeutics (AUTL) had its price target lowered by Mizuho from $12.00 to $10.00. They now have an "outperform" rating on the stock.
Low
Report
Autolus Therapeutics (AUTL) had its price target lowered by Mizuho from $12.00 to $10.00. They now have an "outperform" rating on the stock.
3/27
12:35 pm
autl
Autolus Therapeutics (AUTL) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $10.00 price target on the stock.
Low
Report
Autolus Therapeutics (AUTL) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $10.00 price target on the stock.
3/27
10:23 am
autl
Autolus Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Autolus Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
3/27
07:55 am
autl
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates [Yahoo! Finance]
Low
Report
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates [Yahoo! Finance]
3/27
07:03 am
autl
Autolus Therapeutics GAAP EPS of -$0.34 misses by $0.07, revenue of $24.29M beats by $0.37M [Seeking Alpha]
Low
Report
Autolus Therapeutics GAAP EPS of -$0.34 misses by $0.07, revenue of $24.29M beats by $0.37M [Seeking Alpha]
3/27
07:00 am
autl
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
High
Report
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
3/26
05:49 am
autl
Autolus Therapeutics (AUTL) was upgraded by Truist Financial Corporation to "strong-buy".
Medium
Report
Autolus Therapeutics (AUTL) was upgraded by Truist Financial Corporation to "strong-buy".
3/17
06:52 am
autl
Autolus Therapeutics (AUTL) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
Autolus Therapeutics (AUTL) was upgraded by Zacks Research from "strong sell" to "hold".
3/16
04:33 pm
autl
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026 [Yahoo! Finance]
Low
Report
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026 [Yahoo! Finance]
3/16
04:10 pm
autl
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
Neutral
Report
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
3/10
05:31 pm
autl
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
Low
Report
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
3/10
05:31 pm
autl
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
Low
Report
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
3/5
02:43 am
autl
Autolus Therapeutics Touts $75M Year-1 Obe-cel Launch, Sees $120M-$135M Revenue in 2026 [Yahoo! Finance]
High
Report
Autolus Therapeutics Touts $75M Year-1 Obe-cel Launch, Sees $120M-$135M Revenue in 2026 [Yahoo! Finance]
2/24
07:00 am
autl
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Autolus Therapeutics to Participate in Upcoming Investor Conferences
2/17
07:17 am
autl
Autolus Therapeutics (NASDAQ:AUTL) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
Medium
Report
Autolus Therapeutics (NASDAQ:AUTL) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
2/16
10:15 am
autl
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
Medium
Report
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
2/16
10:15 am
autl
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
Medium
Report
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
2/4
08:57 am
autl
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)